Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Moderna Inc MRNA

Healthcare Biotechnology

Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases, independently and with its strategic collaborators. mRNA medicines are designed to direct the body’s cells to produce intracellular... see more

Add To Watchlist

Recent & Breaking News (NDAQ:MRNA)

Moderna to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, February 23, 2023

Accesswire February 2, 2023

Moderna Granted FDA Breakthrough Therapy Designation for mRNA-1345, An Investigational Respiratory Syncytial Virus (RSV) Vaccine Candidate

Accesswire January 30, 2023

Moderna Announces mRNA-1345, an Investigational Respiratory Syncytial Virus (RSV) Vaccine, Has Met Primary Efficacy Endpoints in Phase 3 Trial in Older Adults

Accesswire January 17, 2023

Moderna Announces Advances Across mRNA Pipeline and Provides Business Update

Accesswire January 9, 2023

CytomX and Moderna Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

GlobeNewswire January 5, 2023

Moderna and CytomX Announce Strategic Research Collaboration for mRNA-Based Conditionally Activated Therapeutics

Accesswire January 5, 2023

Moderna to Acquire OriCiro Genomics

Accesswire January 4, 2023

Moderna to Provide Business and Pipeline Updates at the 2023 J.P. Morgan Healthcare Conference

Accesswire January 3, 2023

Moderna Finalizes Strategic Partnership with UK Government

Accesswire December 21, 2022

Chantal Friebertshäuser Joins Moderna as Senior Vice President, Commercial

Accesswire December 20, 2022

EMA Committee for Medicinal Products for Human Use (CHMP) Recommends the Use of Moderna's BA.1 Targeting Bivalent COVID-19 Booster in Children (6-11 Years) In the European Union

Accesswire December 16, 2022

Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial

Accesswire December 13, 2022

Moderna Receives FDA Emergency Use Authorization for Omicron-Targeting Bivalent COVID-19 Booster Vaccine in Children 6 Months Through 5 Years of Age

Accesswire December 8, 2022

Brad Miller Joins Moderna as Chief Information Officer

Accesswire December 7, 2022

Moderna to Present at the Piper Sandler 34th Annual Healthcare Conference

Accesswire November 29, 2022

David Jiménez Joins Moderna As U.S. General Manager

Accesswire November 17, 2022

Moderna Tops BioSpace's Best Places to Work Ranking for Second Consecutive Year

Accesswire November 16, 2022

Moderna's BA.4/BA.5 Targeting Bivalent Booster, mRNA-1273.222, Meets Primary Endpoint of Superiority Against Omicron Variants Compared to Booster Dose of mRNA-1273 in Phase 2/3 Clinical Trial

Accesswire November 14, 2022

Moderna Shares Environmental, Social and Governance Highlights at First ESG Day

Accesswire November 10, 2022

Moderna to Present at the Jefferies 2022 London Healthcare Conference

Accesswire November 9, 2022